United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $1.32, $0.39 better than the analyst estimate of $0.93. Revenue for the quarter came in at $204.2 million versus the consensus estimate of $203.91 million.

United Therapeutics reaffirmed FY2012 guidance.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.

Earnings